Bringing the fundamentals into focus…
Back to Iovance Biotherapeutics, Inc.
How Iovance Biotherapeutics, Inc. stacks up
IOVA · against 261 other Healthcare companies of similar size
Profitability
16/ 100
Near the bottom of its peers.
Ranked #228 of 262 · scores higher than 12% of peers
Bars: peers in each 10-point band of the profitability score20 peers with a profitability score of 10–19, including IOVA · Click a bar to see the companies
Why profitability scores 16?
Weighted metrics compared with all Healthcare companies.Mainly because of its operating margin, return on invested capital and return on assets, which are weaker than most Healthcare peers.
- a thinner operating margin: weaker than 89% of peers. Operating margin: -151.1% vs peer median 7.1%
- a lower return on invested capital: weaker than 82% of peers. Return on invested capital: -27.7% vs peer median 4.7%
- a lower return on assets: weaker than 81% of peers. Return on assets: -20.3% vs peer median 1.7%
Metric by metric
Position: dot = IOVA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | IOVA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 252 reported | -27.7% | 8.2% | 13% | 33% | |
| Operating marginHigher is better · 239 reported | -151.1% | 10.9% | 8% | 33% | |
| Return on assetsHigher is better · 249 reported | -20.3% | 3.4% | 15% | 33% | |
| Return on equityHigher is better · 245 reported | -40.4% | 7.5% | 16% | Context only | |
| Gross marginHigher is better · 269 reported | 48.4% | 47.6% | 50% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around IOVA| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 321.5B INR (≈$3.9B) | 100 | 70 | |
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 4 | 51.3B ZAR (≈$2.8B) | 99 | 73 | |
| 4 | 3.8B USD | 99 | 71 | |
| 221 | 7.8B USD | 20 | 30 | |
| 226 | 22.1B CNY (≈$3.1B) | 19 | 49 | |
| 227 | 3.1B USD | 18 | 39 | |
| 228 | 4.5B USD | 16 | 33 | |
| 228 | 4.0B USD | 16 | 30 | |
| 228 | 6.0B USD | 16 | 32 | |
| 228 | 2.5B USD | 16 | 31 | |
| 232 | 5.4B USD | 15 | 38 | |
| 233 | 2.7B USD | 14 | 50 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score